Introduction to ORCID and Author Identifiers

Martin Fenner

Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation

Launched as non-profit organization with a Board of Directors in September 2010.

Launch of service planned for 2012.
ORCID Principles

http://www.orcid.org/principles
ORCID will work to support the creation of a permanent, clear and unambiguous record of scholarly communication by enabling reliable attribution of authors and contributors.
Discovery
What other papers were published by co-authors of this paper?

Discovery
What other papers were published by co-authors of this paper?

What datasets were made available by this research project?

Discovery
What other papers were published by co-authors of this paper?

What datasets were made available by this research project?

Discovery

What are the open access papers we published last year?
What other papers were published by co-authors of this paper?

What datasets were made available by this research project?

Discovery

What are the open access papers we published last year?

What papers about a particular topic were published in our country last year?
Evaluation
What is the scholarly record of this job applicant?

Evaluation
What is the scholarly record of this job applicant?  

What was the research output of our institution last year?

Evaluation
What is the scholarly record of this job applicant?

What was the research output of our institution last year?

Evaluation

What papers were published as a result of our funding?
What is the scholarly record of this job applicant?

What was the research output of our institution last year?

Evaluation

What papers were published as a result of our funding?

How often were the papers cited that we published?
ORCID will transcend discipline, geographic, national and institutional boundaries.
http://www.slideshare.net/hratner/orcid-update-aap-psp-annual-meeting-february-2011
Participation in ORCID is open to any organization that has an interest in scholarly communications.
ORCID Participants by Country

United States 81
United Kingdom 39
Germany 17
Australia 7
Canada 5
Spain 5

197 Participants as of March 23, 2011
Access to ORCID services will be based on transparent and non-discriminatory terms posted on the ORCID website.
Researchers will be able to create, edit, and maintain an ORCID ID and profile free of charge.

Researchers will control the defined privacy settings of their own ORCID profile data.
### Personal Information

Update your information. Optionally, use the "public" setting to indicate which information to display on your Profile page. Clear a public check box to make that information private. Note: Click the "Submit Changes" button on each page. * required fields.

<table>
<thead>
<tr>
<th>Field</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>First / Given Name</td>
<td>Martin</td>
</tr>
<tr>
<td>Last / Family Name</td>
<td>Fenner</td>
</tr>
<tr>
<td>Middle Initials</td>
<td>H</td>
</tr>
<tr>
<td>ORCID ID</td>
<td>AAA-1034-2010</td>
</tr>
</tbody>
</table>

- **Public (Master):** Clear the "Public (Master)" check box to make your information private. Only you, when logged in, will be able to view your information.
- **Name:** Your name will be searched and displayed on your profile page.
- **ORCID ID:** This is your unique identification.

<table>
<thead>
<tr>
<th>Field</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other Names by You</td>
<td></td>
</tr>
</tbody>
</table>

- **Public:** If you've published under different names or if you are known by more than one name, enter Other Names. These will be searched if made public.

<table>
<thead>
<tr>
<th>Field</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>URL</td>
<td><a href="http://www.orcidsandbox.org/rid/AAA-1034-2010">http://www.orcidsandbox.org/rid/AAA-1034-2010</a></td>
</tr>
</tbody>
</table>

- **URL:** The URL can be used to link directly to your profile page.

<table>
<thead>
<tr>
<th>Field</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>My URLs</td>
<td></td>
</tr>
</tbody>
</table>

- **My URLs:** You can add up to 3 of your own links (URLs) to your profile page. Enter the entire URL. For example, http://www.thomsonreuters.com
All profile data contributed to ORCID by researchers or claimed by them will be available in standard formats for free download (subject to the researchers' own privacy settings) that is updated once a year and released under the CC0 waiver.
Would ORCID profile information be valuable if not free and open?

n=120 circa

NO

n=119 circa

POSSIBLY

n=45 circa

YES

ORCID Survey October 2010
All software developed by ORCID will be publicly released under an Open Source Software license approved by the Open Source Initiative.

For the software it adopts, ORCID will prefer Open Source.
ORCID plans to license Researcher ID software from Thomson Reuters

First version would be based on that software

Disambiguation service would be added as next step

No decision yet when production system will be launched
**Fenner, Martin H**

**ORCID ID:** AAA-1034-2010

**Other Names:**
- E-mail: fenner.martin@mh-hannover.de
- URL: http://www.orcidsandbox.org/rid/AAA-1034-2010
- Role: Researcher (Academic)
- Subject: Enter a Subject
- Keywords: cancer; orcid

**Description:** Enter a Description

**My Institutions (more details)**

- Primary Institution: Hannover Medical School
  - Sub-org./Dept: 
  - Role: Researcher (Academic)
- Joint Affiliation:
  - Sub-org./Dept: 
  - Role: 
- Past Institutions: Massachusetts General Hospital; Charité

**My External Identifiers:**
- Scopus: 7006600825
- AuthorClaim: pfe2

---

### Publications

#### My Publications: View

13 publication(s)

<table>
<thead>
<tr>
<th>Page</th>
<th>Sort by: Title</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>1.</th>
<th>Title: 61 POSTER Contrast enhanced perfusion CT (CEPCT) predicts early response of sunitinib in renal cell carcinoma (RCC) patients</th>
<th>added 26-Dec-10</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Author(s): GRUNWALDNULLVNULLV</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Source: European Journal of Cancer Supplements Volume: 6 Issue: 12 Pages: 22-22 Published: 2008-10</td>
<td></td>
</tr>
<tr>
<td></td>
<td>DOI: 10.1016/S1359-6349(08)71993-1</td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td>Title: 7046 Effectiveness of Carboplatin (C) plus weekly docetaxel (D) as second-line treatment for docetaxel-resistant, hormone-refractory prostate cancer (HRPC)</td>
<td>added 26-Dec-10</td>
</tr>
<tr>
<td></td>
<td>Author(s): REUTERNULLC.W.M.NULLC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Source: European Journal of Cancer Supplements Volume: 7 Issue: 2 Pages: 420-420 Published: 2009-09</td>
<td></td>
</tr>
<tr>
<td></td>
<td>DOI: 10.1016/S1359-6349(09)71424-7</td>
<td></td>
</tr>
</tbody>
</table>
ORCID identifiers and profile data (subject to privacy settings) will be made available via a combination of no charge and for a fee APIs and services.

Any fees will be set to ensure the sustainability of ORCID as a not-for-profit, charitable organization focused on the long-term persistence of the ORCID system.
Collected $245,000 from 44 organizations in sponsorship drive December 2010 - March 2011

Grant from Mellon Foundation to explore business models for academic institutions March - September 2011

Membership fees planned for 2012

Gap funding required to pay for startup development in 2011-2012
ORCID will be governed by representatives from a broad cross-section of stakeholders, the majority of whom are not-for-profit, and will strive for maximal transparency by publicly posting summaries of all board meetings and annual financial reports.
Current Board of Directors
This presentation can be copied and distributed provided that proper credit is given.